TARS:NSD-Tarsus Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 26.58

Change

-0.41 (-1.52)%

Market Cap

USD 0.97B

Volume

0.39M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

-11.11 (-0.95%)

USD 130.01B
VRTX Vertex Pharmaceuticals Inc

+6.72 (+1.40%)

USD 123.52B
ALNY Alnylam Pharmaceuticals Inc

+3.54 (+1.35%)

USD 33.60B
ARGX argenx NV ADR

+2.24 (+0.42%)

USD 32.41B
MRNA Moderna Inc

-1.40 (-2.01%)

USD 28.23B
BGNE BeiGene Ltd

+2.22 (+1.13%)

USD 20.54B
BMRN Biomarin Pharmaceutical Inc

+0.52 (+0.62%)

USD 17.44B
RPRX Royalty Pharma Plc

+0.17 (+0.62%)

USD 17.14B
UTHR United Therapeutics Corporatio..

-1.99 (-0.58%)

USD 15.72B
PCVX Vaxcyte Inc

+1.87 (+1.64%)

USD 14.27B

ETFs Containing TARS

IHE iShares U.S. Pharmaceutic.. 1,000.00 % 0.42 %

+0.35 (+2.53%)

N/A
SLX VanEck Steel ETF 5.12 % 0.56 %

+1.31 (+2.53%)

N/A
XME SPDR® S&P Metals and Min.. 4.94 % 0.35 %

+1.46 (+2.53%)

N/A
FXZ First Trust Materials Alp.. 4.71 % 0.64 %

+1.18 (+2.53%)

N/A
PYZ Invesco DWA Basic Materia.. 4.15 % 0.60 %

+1.74 (+2.53%)

USD 0.06B
SMLL 3.53 % 0.28 %

N/A

N/A
XMHQ Invesco S&P MidCap Qualit.. 2.14 % 0.25 %

+1.89 (+2.53%)

USD 5.04B
IVOG Vanguard S&P Mid-Cap 400 .. 1.19 % 0.20 %

+1.80 (+2.53%)

USD 1.02B
MDYG SPDR® S&P 400 Mid Cap Gr.. 1.12 % 0.15 %

+1.21 (+2.53%)

N/A
ZMID:CA BMO S&P US Mid Cap Index .. 0.63 % 0.00 %

+1.09 (+2.53%)

N/A
MDY SPDR® S&P MIDCAP 400 ETF.. 0.62 % 0.24 %

+9.52 (+2.53%)

USD 21.50B
SPY4:LSE SPDR® S&P 400 US Mid Cap.. 0.62 % 0.00 %

+1.73 (+2.53%)

N/A
SPY4:F SSgA SPDR S&P 400 US Mid .. 0.62 % 0.00 %

+1.18 (+2.53%)

N/A
SPY4:XETRA SSgA SPDR S&P 400 US Mid .. 0.62 % 0.00 %

+1.10 (+2.53%)

USD 1.99B
IVOO Vanguard S&P Mid-Cap 400 .. 0.61 % 0.15 %

+1.86 (+2.53%)

USD 2.12B
SPMD SPDR Russell Small Cap Co.. 0.58 % 0.06 %

+0.93 (+2.53%)

USD 10.60B
VBR Vanguard Small-Cap Value .. 0.51 % 0.07 %

+3.86 (+2.53%)

USD 28.76B
MVV ProShares Ultra MidCap400 0.46 % 0.95 %

+2.28 (+2.53%)

USD 0.13B
MIDU Direxion Daily Mid Cap Bu.. 0.41 % 1.10 %

+2.51 (+2.53%)

USD 0.09B
UMDD ProShares UltraPro MidCap.. 0.35 % 0.95 %

+1.21 (+2.53%)

USD 0.03B
SMLF iShares MSCI USA Small-Ca.. 0.00 % 0.30 %

+1.37 (+2.53%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 31.26% 76% C+ 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 31.26% 76% C+ 86% B+
Trailing 12 Months  
Capital Gain 51.97% 82% B 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 51.97% 82% B 89% A-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 4.97% 61% D- 58% F
Dividend Return 4.97% 61% D- 55% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 50.99% 61% D- 35% F
Risk Adjusted Return 9.75% 69% C- 47% F
Market Capitalization 0.97B 80% B- 71% C-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector